In addition to conventional clinical factors such as tumor size, stage, functional activity, total Weiss score, and Ki67 proliferation index, a number of molecular markers have recently been recognized to improve accuracy for survival prediction [2–5], particularly in metastatic cases [6, 7]. Here, MKI67 is linked to neoplasm.